Jing Lou, Ph.D., (GSAS ’94), founder, chief executive officer and director of 3SBio Inc., presided over the closing bell of the NASDAQ Stock Market on Feb. 12, to celebrate the company’s initial public offering.
3SBio is a biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. Its product line includes protein-based therapeutics designed to fight cancer, arthritis and autoimmune diseases.
Jing received his medical degree from Shanghai Second Military Medical University in 1985, and did his doctoral work in molecular biology, researching interferon signal transduction of gene regulation in the laboratory of Berish Y. Rubin, Ph.D., professor of biological sciences at Fordham’s Graduate School of Arts and Sciences. Jing was awarded a National Academy of Sciences research associateship and was inducted as a member of the Phi Beta Kappa Society upon graduation.
“He was a very talented, bright young man, and very motivated,” said Rubin of his former graduate student. “He’s been a star and has done extremely well academically and in terms of business, and now’s he’s been able to blend the two.”
Jing completed his postdoctoral study at the U.S. National Institute of Health in 1995. He founded Lifegen, Inc., a Maryland-based biotechnology corporation, and has been in his current position since 2000.
